|
1
|
Perkins C, Balma D, Garcia R; Members of
the Consensus Group, ; Susan G: Komen for the cure: Why current
breast pathology practices must be evaluated. A Susan G. Komen for
the Cure white paper: June 2006. Breast J. 13:443–447. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hass GP, Delongchamps N, Brawley OW, Wang
CY and de la Roza G: The worldwide epidemiology of prostate cancer:
Perspectives from autopsy studies. Can J Urol. 15:3866–3871.
2008.PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network, .
The molecular taxonomy of primary prostate cancer. Cell.
163:1011–1025. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part 1:
Screening, diagnosis, and local treatment with curative
intent-update 2013. Eur Urol. 65:124–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tetreault-Laflamme A and Crook J: Options
for salvage of radiation failures for prostate cancer. Semin Radiat
Oncol. 27:67–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sternberg CN: Novel hormonal therapy for
castration-resistant prostate cancer. Ann Oncol. 23 (Suppl
10):x259–x263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suzuki H, Maruyama R, Yamamoto E and Kai
M: Epigenetic alteration and microRNA dysregulation in cancer.
Front Genet. 4:2582013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramalho-Carvalho J, Fromm B, Henrique R
and Jerónimo C: Deciphering the function of non-coding RNAs in
prostate cancer. Cancer Metastasis Rev. 35:235–262. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stefani G and Slack FJ: A ‘pivotal’ new
rule for microRNA-mRNA interactions. Nat Struct Mol Biol.
19:265–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Guan Y, Lu YY, Hu YY, Huang S and
Su SB: Circulating miR-583 and miR-663 refer to ZHENG
differentiation in chronic hepatitis B. Evid Based Complement
Alternat Med. 2013:7513412013.PubMed/NCBI
|
|
14
|
Cakmak HA, Coskunpinar E, Ikitimur B,
Barman HA, Karadag B, Tiryakioglu NO, Kahraman K and Vural VA: The
prognostic value of circulating microRNAs in heart failure:
Preliminary results from a genome-wide expression study. J
Cardiovasc Med (Hagerstown). 16:431–437. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yun S, Lee SU, Kim JM, Lee HJ, Song HY,
Kim YK, Jung H, Park YJ, Yoon SR, Oh SR, et al: Integrated
mRNA-microRNA profiling of human NK cell differentiation identifies
MiR-583 as a negative regulator of IL2Rγ expression. PLoS One.
9:e1089132014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edwardson MA, Zhong X, Fiandaca MS,
Federoff HJ, Cheema AK and Dromerick AW: Plasma microRNA markers of
upper limb recovery following human stroke. Sci Rep. 8:125582018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiong DD, Dang YW, Lin P, Wen DY, He RQ,
Luo DZ, Feng ZB and Chen G: A circRNA-miRNA-mRNA network
identification for exploring underlying pathogenesis and therapy
strategy of hepatocellular carcinoma. J Transl Med. 16:2202018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pashaei E, Pashaei E, Ahmady M, Ozen M and
Aydin N: Meta-analysis of miRNA expression profiles for prostate
cancer recurrence following radical prostatectomy. PLoS One.
12:e01795432017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beermann J, Piccoli MT, Viereck J and Thum
T: Non-coding RNAs in development and disease: Background,
mechanisms, and therapeutic approaches. Physiol Rev. 96:1297–1325.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen JY, Xu LF, Hu HL, Wen YQ, Chen D and
Liu WH: MiRNA-215-5p alleviates the metastasis of prostate cancer
by targeting PGK1. Eur Rev Med Pharmacol Sci. 24:639–646.
2020.PubMed/NCBI
|
|
22
|
Rotundo F, Cominetti D, EI Bezawy R,
Percio S, Doldi V, Tortoreto M, Zuco V, Valdagni R, Zaffaroni N and
Gandellini P: miR-1272 exerts tumor-suppressive functions in
prostate cancer via HIP1 suppression. Cells. 9:4352020. View Article : Google Scholar
|
|
23
|
Li Z, Zhao S, Wang H, Zhang B and Zhang P:
miR-4286 promotes prostate cancer progression via targeting the
expression of SALL1. J Gene Med. e31272019.(Epub ahead of print).
PubMed/NCBI
|
|
24
|
Sartor O and de Bono JS: Metastatic
prostate cancer. N Engl J Med. 378:645–657. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhagirath D, Yang TL, Dahiya R and Saini
S: MicroRNAs as regulators of prostate cancer metastasis. Adv Exp
Med Biol. 1095:83–100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu DL, Zhang T, Wu K, Li Y, Wang J, Chen
J, Li XQ, Peng XG, Wang JN and Tan LG: MicroRNA-448 suppresses
metastasis of pancreatic ductal adenocarcinoma through targeting
JAK1/STAT3 pathway. Oncol Rep. 38:1075–1082. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Du J, Jiang R and Li L:
MicroRNA-214 inhibits the proliferation and invasion of lung
carcinoma cells by targeting JAK1. Am J Transl Res. 10:1164–1171.
2018.PubMed/NCBI
|
|
28
|
Zhou Y, Xu XM and Feng Y: MiR-769-5p
inhibits cancer progression in oral squamous cell carcinoma by
directly targeting JAK1/STAT3 pathway. Neoplasma. 67:528–536. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu L, Talati P, Vogiatzi P, Romero-Weaver
AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, et
al: Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480
potently inhibits IL-6-induced experimental prostate cancer
metastases formation. Mol Cancer Ther. 13:1246–1258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dai H, Wang C, Yu Z, He D, Yu K, Liu Y and
Wang S: MiR-17 regulates prostate cancer cell proliferation and
apoptosis through inhibiting JAK-STAT3 signaling pathway. Cancer
Biother Radiopharm. 33:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JH, Kim C, Baek SH, Ko JH, Lee SG,
Yang WM, Um JY, Sethi G and Ahn KS: Capsazepine inhibits JAK/STAT3
signaling, tumor growth, and cell survival in prostate cancer.
Oncotarget. 8:17700–17711. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Z, Huang W, Chen B, Bai PD, Wang XG and
Xing JC: Up-regulation of miR-124 inhibits invasion and
proliferation of prostate cancer cells through mediating JAK-STAT3
signaling pathway. Eur Rev Med Pharmacol Sci. 21:2338–2345.
2017.PubMed/NCBI
|
